New drug shows promise in controlling rare fat disorder
NCT ID NCT05130450
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 25 times
Summary
This study looks at how well the drug olezarsen works over time to lower fat levels in the blood of people with familial chylomicronemia syndrome (FCS), a rare genetic condition. About 60 participants who completed a prior study will receive the drug for up to 3 years. The main goal is to see if fasting triglycerides drop significantly and stay lower.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL CHYLOMICRONEMIA SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Academisch Medisch Centrum Goederenontvangst Apotheek t.a.v. Kenniscentrum
Amsterdam, Noor-Holland, 1105 AZ, Netherlands
-
Apokteket AB
Malmö, 211 24, Sweden
-
Azienda Ospedaliero Universitaria Policlinico Umberto I
Rome, 00161, Italy
-
CTSI Investigational Pharmacy
New York, New York, 10016, United States
-
Clinique des Maladies Lipidiques de Quebec Inc.
Québec, Quebec, G1V 4W2, Canada
-
Department of Pharmacy
Park Ridge, Illinois, 60068, United States
-
Diabetes/Lipid Management & Research Center
Huntington Beach, California, 92648, United States
-
Dra Margarida Falcao Centro Hospitalar Lisboa Ocidental Hospital Egas Moniz
Lisbon, 1340-019, Portugal
-
Ecogene-21
Chicoutimi, Quebec, G7H 7K9, Canada
-
Excel Medical Clinical Trials, LLC
Boca Raton, Florida, 33434, United States
-
Groupement Hospitalier Est- Pharmacie Secteur Essais Clinique
Bron, 69677, France
-
Hospital Clínic Barcelona C/ Villarroel
Barcelona, 08036, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Virgen del Rocío
Seville, 41013, Spain
-
Hospital da Senhora da Oliveira Guimaraes
Creixomil, 4835-044, Portugal
-
Hôpital Bicêtre
Le Kremlin-Bicêtre, 94270, France
-
IDS Central
Philadelphia, Pennsylvania, 19104, United States
-
Institute de Recherches Cliniques de Montreal
Montreal, Quebec, H2W 1R7, Canada
-
Metabolicke centrum MU
Bratislava, 83101, Slovakia
-
Milstein Hospital
New York, New York, 10032, United States
-
Nathalie Saint-Pierre
Montreal, Quebec, H2W 1R7, Canada
-
Oslo Hospital Pharmacy Rikshospitalet
Oslo, 0372, Norway
-
Pharmacie Hopital de la Conception
Marseille, 05 13385, France
-
Royal Manchester Children's Hospital
Manchester, M13 9WL, United Kingdom
-
UOC di Farmacia AOUP PAOLO GIACCONE
Palermo, 90127, Italy
-
University of Kansas Medical Center (KUMC)
Kansas City, Kansas, 66160, United States
-
Via Sergio Pansini 5
Naples, 80131, Italy
Conditions
Explore the condition pages connected to this study.